Vous avez cherché: predisposing (Anglais - Maltais)

symptomatic hypocalcaemia, often in association with predisposing conditions.§
ipokalċimja bis-sintomi, sikwit marbuta ma’ kundizzjonijiet li jippredisponu għaliha.§

can the predisposing factor be reduced, e.g. by vaccination?
jista’ l-fattur ta’ predisposizzjoni jkun imnaqqas, eżempju bit-tilqim?

fluid retention may be a predisposing factor for signs and symptoms of heart failure.
iż- żamma tal- fluwidu jista 'jippredisponi għal sinjali u sintomi ta' attakk ta 'qalb.

coagulation parameters should be monitored in patients with conditions predisposing to bleeding, such as anticoagulant use.
il-parametri ta’ koagulazzjoni għandhom jiġu ċċekkjati f’pazjenti li għandhom kondizzjonijiet li jistgħu jwasslu għal problemi ta’ fsada bħall-użu ta’ antikoagulanti.

in some cases, a prior increase in body weight has been reported which may be a predisposing factor.
f’xi każijiet, ġiet irrapurtata żieda fil-piż tal-ġisem li tista’ tkun fattur ta’ predisposizzjoni.

caution is recommended in patients with epilepsy, former history of convulsions or patients with predisposing factors for epilepsy.
hija rakkomandata l-attenzjoni f’pazjenti li jbatu b’epilessija, passat ta’ aċċessjonijiet jew pazjenti li għandhom fatturi li minħabba fihom ikollhom tendenza għall-epilessija.

however, there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposing factors.)
madankollu, m’hemm l-ebda evidenza li l- inċidenza ta’ lewkimja tiżdied f’persuni li jirċievu l-ormon tat-tkabbir mingħajr fatturi ta’ predisposizzjoni.)

a theoretical risk for the development of systemic activation of the coagulation system in patients suffering from underlying diseases predisposing them to dic cannot be totally excluded.
riskju teoretiku għall-iżvilupp ta’ attivazzjoni sistemika tas-sistema tal-koagulazzjoni f’pazjenti li jbatu minn mard ieħor li jippredisponuhom għall-dic, ma jistax jiġi eskluż għal kollox.

in patients with a predisposing risk due to previous prolonged, systemic aminoglycoside therapy it may be necessary to consider renal and audiological assessment before initiating tobi podhaler therapy.
f’pazjenti li diġà jinsabu f’riskju minħabba terapija sistemika mgħoddija u mtawla b’aminoglikosidi, jaf ikun meħtieġ li wieħed jikkunsidra li jagħmel evalwazzjoni renali u awdjoloġika qabel ma tinbeda t-terapija b’tobo podhaler.

blood counts and coagulation parameters should be monitored in patients with conditions predisposing to bleeding, and in those treated with anticoagulants or other concomitant medicinal products that increase the risk of bleeding.
l-għadd tad-demm u l-parametri ta’ koagulazzjoni għandhom jiġu sorveljati f’pazjenti b’kundizzjonijiet li jippredisponuhom għall-fsada, kif ukoll f’dawk ikkurati b’antikoagulanti jew li fl- istess żmien qed jingħataw prodotti mediċinali oħra li jżidu r-riskju ta’ fsada.

hepatic events during post marketing use have mainly been reported in patients with predisposing factors, e.g. history of transaminase elevations before start of kineret treatment.
avvenimenti epatiċi waqt l-użu wara t-tqegħid fis-suq kienu prinċipalment irrapportati f’pazjenti b’fatturi ta’ predispożizzjoni, eż. storja ta’ żieda fit-transaminażi qabel il-bidu tal-kura b’kineret.

patients with a history of seizures or other predisposing factors (see section 4.4) should be advised of the risk of driving or operating machines.
pazjenti b’passat ta’ aċċessjonijiet jew fatturi oħra li jippredisponuhom għal aċċessjonijiet (ara sezzjoni 4.4) għandhom jiġu rakkomandati dwar ir-riskju li jsuqu jew iħaddmu magni.

use with caution in patients who have had myopathy or rhabdomyolysis in the past or have any predisposing issues including other medicinal products associated with these conditions (see section 4.8).
uża b’kawtela f’pazjenti li kellhom mijopatija jew rhabdomyolysis fil-passat jew li jbatu minn sitwazzjonijiet predisposti inkluż mediċini oħra assoċjati ma’ dawn il-kundizzjonijiet (ara sezzjoni 4.8).

all of these arrhythmias either occurred in the context of a mabthera infusion or were associated with predisposing conditions such as fever, infection, acute myocardial infarction or pre-existing respiratory and cardiovascular disease.
dawn l-arritmiji kollha seħħew fil-kuntest ta’ infużjoni ta’ mabthera jew kienu assoċjati ma’ kudizzjonijiet li jippredisponu bħal deni, infezzjoni, infart mijokardijaku akut jew mard respiratorju u kardjovaskulari eżistenti minn qabel.

as ivabradine may cause bradycardia, the resulting combination of hypokalemia and bradycardia is a predisposing factor to the onset of severe arrhythmias, especially in patients with long qt syndrome, whether congenital or substance-induced.
minħabba li ivabradine jista' jikkawża bradikarja, il-kombinazzjoni li tirriżulta ta' ipokalemja u bradikarja hija fattur ta' predispożizzjoni għall-feġġa ta' arritmiji severi b'mod speċjali f'pazjenti b'sindromu qt twil, kemm jekk konġenitali kif ukoll jekk indotti minn sustanza.

based on the available data, no predisposing factors (e.g. tumour size, tumour location, coagulation disorders) have been identified that place patients with gist at a higher risk of either type of haemorrhage.
mit-tagħrif disponibbli, ma ġewx identifikati fatturi li jżidu r-riskju (eż daqs tat-tumur, post fejn ikun it-tumur, mard tal-koagulazzjoni) li jżidu r-riskju taż-żewġ tipi ta’ emorraġiji f’pazjenti li jsofru minn gist.